Literature DB >> 27987586

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.

Delphine Levacq1, Nicky D'Haene2, Roland de Wind3, Myriam Remmelink2, Thierry Berghmans4.   

Abstract

Various mechanisms of resistance to ALK inhibitors in ALK rearranged adenocarcinomas are reported including secondary gatekeeper mutations, bypass signaling or ALK amplifications as the commonest ones. We report a new mechanism of resistance with transformation of adenocarcinoma into small cell lung cancer. A 53-year-old non-smoker woman, experienced cancer progression after two lines of ALK inhibitors. A new biopsy showed a small cell lung cancer. FISH revealed persistent ALK rearrangement with an atypical pattern and complete loss of the 5' region of the ALK gene.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ALK translocation; Lung neoplasms; Small cell cancer transformation

Mesh：

Substances：

Year:  2016        PMID： 27987586     DOI： 10.1016/j.lungcan.2016.10.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  18 in total

Review 1.  Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.

Authors:  Solange Peters; Stefan Zimmermann
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 2.  Histologic transformation in lung cancer: when one door shuts, another opens.

Authors:  Yuki Sato; Go Saito; Daichi Fujimoto
Journal:  Ther Adv Med Oncol       Date:  2022-10-14       Impact factor: 5.485

3.  Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.

Authors:  Xianjin Xie; Xudong Chen; Ningning Luo; Yingxue Qi; Mengmeng Li; Xiaoya Feng
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-15       Impact factor: 4.322

Review 4.  Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.

Authors:  Laura J Tafe
Journal:  Virchows Arch       Date:  2017-03-10       Impact factor: 4.064

5.  Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

Authors:  Jongmin Sim; Hyunjin Kim; Jiyeon Hyeon; Yoon La Choi; Joungho Han
Journal:  J Korean Med Sci       Date:  2018-04-09       Impact factor: 2.153

Review 6.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639

Review 7.  Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.

Authors:  Julian Pinsolle; Anne McLeer-Florin; Matteo Giaj Levra; Florence de Fraipont; Camille Emprou; Elisa Gobbini; Anne-Claire Toffart
Journal:  Front Med (Lausanne)       Date:  2019-10-29

8.  Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report.

Authors:  You-Cai Zhu; Xing-Hui Liao; Wen-Xian Wang; Chun-Wei Xu; Wu Zhuang; Li-Hua Zhong; Kai-Qi Du; Yan-Ping Chen; Gang Chen; Mei-Yu Fang
Journal:  Onco Targets Ther       Date:  2017-06-27       Impact factor: 4.147

9.  Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition.

Authors:  Jessica J Lin; Adam Langenbucher; Pranav Gupta; Satoshi Yoda; Isobel J Fetter; Marguerite Rooney; Andrew Do; Marina Kem; Kylie Prutisto Chang; Audris Y Oh; Emily Chin; Dejan Juric; Ryan B Corcoran; Ibiayi Dagogo-Jack; Justin F Gainor; James R Stone; Jochen K Lennerz; Michael S Lawrence; Aaron N Hata; Mari Mino-Kenudson; Alice T Shaw
Journal:  NPJ Precis Oncol       Date:  2020-08-03

Review 10.  Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer.

Authors:  Tatiana Shaurova; Letian Zhang; David W Goodrich; Pamela A Hershberger
Journal:  Front Genet       Date:  2020-03-27       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.